Evidence map›Paper›PMID 42393731›Full record

ArticleAnnals of clinical microbiology and antimicrobials2026

Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China.

Wei Shu, Qingshan Cai, Yuping Huang, Yuanhong Xu, Yuanyuan Shang, Ruixia Liang, Liang Yan, Lin Wang, Long Jin, Yi Pei and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wei Shu *Clinical Center on TB, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, P.R. China.
Qingshan Cai *Department of Tuberculosis, Hangzhou Red Cross Hospital, Zhejiang Tuberculosis Diagnosis and Treatment Center, Hangzhou, P.R. China.
Yuping Huang *Department of Laboratory Medicine, Chest Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, P.R. China.
Yuanhong Xu *Department of Laboratory Medicine, Chengdu Public Health Clinical Center, Chengdu, P.R. China.
Yuanyuan Shang *Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, P.R. China.
Ruixia LiangTuberculosis Department, Henan Chest Hospital, Zhengzhou, P.R. China.
Liang YanDepartment of Laboratory Medicine, Jiangxi Chest Hospital, Nanchang, P.R. China.
Lin WangDepartment of Laboratory Medicine, The Third People's Hospital of Kunming, Kunming, P.R. China.
Long JinThe Eight Wards of Tuberculosis Internal Medicine, Infectious Hospital of Heilongjiang Province, Harbin, P.R. China.
Yi PeiDepartment of Tuberculosis, Changsha Central Hospital, Changsha, P.R. China.
Zhongfeng HuangThe Drug-Resistant Tuberculosis Division, Guiyang Public Health Treatment Center, Guiyang, P.R. China.
Shanshan LiDepartment of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, P.R. China.
Yufeng WangDepartment of Laboratory Quality Control, Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing), Beijing, P.R. China.
Mengqiu GaoDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, P.R. China.
Liang LiClinical Center on TB, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, P.R. China. liliang69@tb123.org.
Yu PangDepartment of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, P.R. China. pangyupound@163.com.

Funding

Beijing Hospital Management Center "Dengfeng" Talent Training Program DFL20221401Beijing Municipal Health Commission High Level Public Health Talent Construction Project Discipline Leader 03-11Beijing Municipal Science & Technology Commission Z221100007422064Program of Beijing Research Ward Excellence Program, BRWEP BRWEP2024W042160101Program of Tongzhou District Science & Technology Commission JCQN2023015
6 · The paper itself

Abstract

backgroundDelamanid (DLM) is a promising drug recommended for treatment of multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB). However, there are very little data about the emergence of drug resistance in patients with the use of DLM-containing regimens. The study aimed to monitor the dynamics of susceptibility of MTB to DLM and investigate the potential mechanism conferring decreased susceptibility.

methodsA prospective cohort study was conducted, enrolling MDR/RR-TB patients with culture-confirmed diagnoses across 10 study sites. Serial sputum samples were collected from participants receiving DLM-containing regimens at baseline (treatment initiation), week 2, week 4, and every 4 weeks thereafter until treatment completion. The in vitro susceptibility of Mycobacterium tuberculosis isolates to DLM was assessed using the BACTEC MGIT 960 system.

resultsA total of 263 MDR/RR-TB patients were included from 2020 to 2024 in the present study, favorable outcomes were recorded in 187 patients (71.1%). The distribution of minimal inhibit concentration (MIC) for a bacterial population to DLM was unimodal, and most isolates tested had a MIC value of < 0.015 µg/mL. The MIC

conclusionsPrimary DLM resistance was rare (0.76%), and resistance emergence during treatment was infrequent, though some cases of reduced susceptibility were observed.

Indexed as

Antitubercular AgentsDrug Resistance, Multiple, BacterialMycobacterium tuberculosisNitroimidazolesOxazolesRifampinTuberculosis, Multidrug-ResistantAdultChinaFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedProspective StudiesAntitubercular AgentsNitroimidazolesOPC-67683OxazolesRifampinDelamanid resistanceMultidrug-/Rifampicin-resistantTuberculosis

Identifiers

PMID42393731
PMCPMC13326454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.